Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare and Medicaid Services Mehmet Oz in the Oval Office in Washington, D.C., U.S., April 18, 2025. REUTERS/Nathan Howard/File Photo

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.